Changes in Beneficial Ownership · 4
Editas Medicine, Inc.
EDITNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1788553659.xml
Filing details
- Report period
- 2026-09-03
- Issuer
- Editas Medicine, Inc.
- Issuer CIK
- 0001650664
- Trading symbol
- EDIT
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Burkly Linda
- Reporting owner CIK
- 0001985604
- Relationship
- Officer
- Officer title
- EVP, CHIEF SCIENTIFIC OFFICER
- Address
- 11 HURLEY ST., CAMBRIDGE, MA, 02141
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-03 | S · Form 4[F1] | 709 | D | 3.0372[F2] | 61,660 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.↩ 1
- F2
- This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.↩ 1
Signature 1
- Signed
- /s/ Linda C. Burkly
- Date
- 2026-09-04
Company context
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.